These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
710 related articles for article (PubMed ID: 20887966)
21. Comparison of HAS-BLED and HAS-BED Versus CHADS Poli D; Antonucci E; Pengo V; Testa S; Palareti G Am J Cardiol; 2017 Apr; 119(7):1012-1016. PubMed ID: 28237286 [TBL] [Abstract][Full Text] [Related]
22. Can we predict stroke in atrial fibrillation? Lip GY Clin Cardiol; 2012 Jan; 35 Suppl 1(Suppl 1):21-7. PubMed ID: 22246948 [TBL] [Abstract][Full Text] [Related]
23. A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation. Lip GY; Potpara T; Boriani G; Blomström-Lundqvist C J Intern Med; 2016 May; 279(5):467-76. PubMed ID: 27001354 [TBL] [Abstract][Full Text] [Related]
24. Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. Lip GY; Connolly S; Yusuf S; Shestakovska O; Flaker G; Hart R; Lanas F; Xavier D; Eikelboom J; Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):31-8. PubMed ID: 23390125 [TBL] [Abstract][Full Text] [Related]
25. Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants. Guo Y; Lip GY; Apostolakis S Hosp Pract (1995); 2013 Feb; 41(1):71-8. PubMed ID: 23466969 [TBL] [Abstract][Full Text] [Related]
26. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med; 1996 Feb; 156(4):409-16. PubMed ID: 8607726 [TBL] [Abstract][Full Text] [Related]
27. Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, and Health cohort study. Larsen TB; Lip GY; Skjøth F; Due KM; Overvad K; Hvilsted Rasmussen L Circ Cardiovasc Qual Outcomes; 2012 May; 5(3):335-42. PubMed ID: 22534406 [TBL] [Abstract][Full Text] [Related]
28. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Lip GY; Andreotti F; Fauchier L; Huber K; Hylek E; Knight E; Lane DA; Levi M; Marin F; Palareti G; Kirchhof P; ; Collet JP; Rubboli A; Poli D; Camm J Europace; 2011 May; 13(5):723-46. PubMed ID: 21515596 [TBL] [Abstract][Full Text] [Related]
29. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Poli D; Antonucci E; Grifoni E; Abbate R; Gensini GF; Prisco D Thromb Haemost; 2009 Feb; 101(2):367-72. PubMed ID: 19190823 [TBL] [Abstract][Full Text] [Related]
30. Comparison of the CHA Yao X; Gersh BJ; Sangaralingham LR; Kent DM; Shah ND; Abraham NS; Noseworthy PA Am J Cardiol; 2017 Nov; 120(9):1549-1556. PubMed ID: 28844514 [TBL] [Abstract][Full Text] [Related]
31. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. Rockson SG; Albers GW J Am Coll Cardiol; 2004 Mar; 43(6):929-35. PubMed ID: 15028346 [TBL] [Abstract][Full Text] [Related]
32. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Coppens M; Eikelboom JW; Hart RG; Yusuf S; Lip GY; Dorian P; Shestakovska O; Connolly SJ Eur Heart J; 2013 Jan; 34(3):170-6. PubMed ID: 23018151 [TBL] [Abstract][Full Text] [Related]
33. Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation. Overvad TF; Larsen TB; Albertsen IE; Rasmussen LH; Lip GY Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1619-29. PubMed ID: 24215192 [TBL] [Abstract][Full Text] [Related]
34. Prevalence of undiagnosed atrial fibrillation and of that not being treated with anticoagulant drugs: the AFABE study. Clua-Espuny JL; Lechuga-Duran I; Bosch-Princep R; Roso-Llorach A; Panisello-Tafalla A; Lucas-Noll J; López-Pablo C; Queralt-Tomas L; Giménez-Garcia E; González-Rojas N; Gallofré López M Rev Esp Cardiol (Engl Ed); 2013 Jul; 66(7):545-52. PubMed ID: 24776203 [TBL] [Abstract][Full Text] [Related]
35. Safety of percutaneous left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation. Wiebe J; Bertog S; Franke J; Wettstein O; Lehn K; Hofmann I; Vaskelyte L; Sievert H Catheter Cardiovasc Interv; 2014 Apr; 83(5):796-802. PubMed ID: 24327462 [TBL] [Abstract][Full Text] [Related]
36. [Anticoagulation in atrial fibrillation. Strategies in special situations]. Volkmann H; Walter M; Walter C; Vetter S Clin Res Cardiol Suppl; 2011 May; 6():58-65. PubMed ID: 22528179 [TBL] [Abstract][Full Text] [Related]
37. Fecal hemoglobin excretion in elderly patients with atrial fibrillation: combined aspirin and low-dose warfarin vs conventional warfarin therapy. Blackshear JL; Baker VS; Holland A; Litin SC; Ahlquist DA; Hart RG; Ellefson R; Koehler J Arch Intern Med; 1996 Mar; 156(6):658-60. PubMed ID: 8629878 [TBL] [Abstract][Full Text] [Related]
38. CHA2DS2-VASc score is directly associated with the risk of pulmonary embolism in patients with atrial fibrillation. Saliba W; Rennert G Am J Med; 2014 Jan; 127(1):45-52. PubMed ID: 24384101 [TBL] [Abstract][Full Text] [Related]
39. What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation? Lip GY J R Coll Physicians Edinb; 2012; 42 Suppl 18():35-44. PubMed ID: 22518392 [TBL] [Abstract][Full Text] [Related]
40. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? Chao TF; Liu CJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chen TJ; Lip GY; Chen SA J Am Coll Cardiol; 2015 Feb; 65(7):635-42. PubMed ID: 25677422 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]